SS Innovations International (NASDAQ: SSII) has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital in Ahmedabad, India. The program commenced with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra 3.0 system. This development marks a significant step in the adoption of robotic-assisted cardiac procedures in the region and underscores the growing global reach of SS Innovations' technology.
The launch of this program at HCG Hospital is important because it demonstrates the expanding application of the SSi Mantra system beyond general surgery into specialized cardiac procedures. Cardiac surgery is a complex field where robotic assistance can offer benefits such as smaller incisions, reduced pain, and faster recovery times. By enabling hospitals to perform such advanced procedures, SS Innovations is positioning itself as a key player in the global surgical robotics market. The company's commitment to advancing robotic cardiac surgery is evident in its collaboration with leading surgeons and institutions like HCG Hospital.
SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. This rapid adoption reflects the increasing demand for affordable and effective robotic surgical solutions worldwide. The company is also pursuing U.S. FDA review and European Union CE marking as it seeks to expand the SSi Mantra into additional international markets. These regulatory milestones, if achieved, could further accelerate the system's adoption in high-value markets and enhance the company's competitive position.
The successful launch at HCG Hospital is a testament to the trust that healthcare providers place in SS Innovations' technology. In a LinkedIn post, the company congratulated Dr. Brajmohan Singh, Dr. Lalit Malik, and the entire team at HCG Hospital for their achievement, thanking them for their trust and commitment to advancing robotic cardiac surgery in the region. For more details, the company's newsroom is available at https://ibn.fm/SSII. Additionally, the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN can be found at https://IBN.ai/Disclaimer.
This expansion is important for investors and the medical community because it signals SS Innovations' ability to penetrate new surgical specialties and geographies. As the company continues to grow its installed base and pursue regulatory approvals, it could capture a larger share of the robotic surgery market, which is currently dominated by a few major players. The successful cardiac program at HCG Hospital may serve as a reference site for other hospitals considering robotic cardiac surgery, potentially driving further adoption. For more information, visit SS Innovations International (NASDAQ: SSII) or read the original release on www.newmediawire.com.
